Home
Resources
Publications
Beclomethasone Dipropionate Hydrofluoroalkane for the Treatment of Allergic Rhinitis

Beclomethasone Dipropionate Hydrofluoroalkane for the Treatment of Allergic Rhinitis

Giuliana Ferrante, Laura Montalbano, Giovanna Cilluffo, Velia Malizia, Donatella Marchese, Stefania La Grutta

Expert Rev Clin Immunol. 2016;12(3):279-88.

PMID: 26558604

Abstract:

Allergic rhinitis (AR) is a common respiratory disease, and its prevalence is increasing all over the world, both in adults and in children. Patients experience symptoms that may negatively impact on physical, social and psychological well-being. Hence, if left untreated, allergic rhinitis may significantly affect quality of life. Under current guidelines, intranasal corticosteroids are considered the most effective drugs and they are recommended as first-line therapy. Among the several corticosteroid intranasal sprays available, beclomethasone dipropionate is one of the most prescribed. Recently, new intranasal hydrofluoroalkane-propelled formulations with little or no impact on the ozone layer have been developed for the treatment of AR. The use of these devices might improve patients' adherence to treatment, avoiding some of the most common side effects associated with aqueous formulations. This review provides the most recent evidence for the efficacy and safety of beclomethasone dipropionate hydrofluoroalkane nasal aerosol in the treatment of allergic rhinitis.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP5534098-A	Beclomethasone Dipropionate		5534-09-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: